Cycloset is a brand name of bromocriptine, approved by the FDA in the following formulation(s):
CYCLOSET (bromocriptine mesylate - tablet; oral)
Manufacturer: VEROSCIENCE
Approval date: May 5, 2009
Strength(s): EQ 0.8MG BASE [RLD]
Has a generic version of Cycloset been approved?
No. There is currently no therapeutically equivalent version of Cycloset available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cycloset. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Therapeutic process for the treatment of the pathologies of Type II diabetes
Patent 5,468,755
Issued: November 21, 1995
Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.Patent expiration dates:
- November 21, 2012✓
- November 21, 2012
Accelerated release composition containing bromocriptine
Patent 5,679,685
Issued: October 21, 1997
Inventor(s): Cincotta; Anthony H. & Cincotta, Jr.; Manuel & Pelloni; Christopher Louis & Runice; Christopher Eric & Tigner; Sandra Louise
Assignee(s): Ergo Science, Incorporated
Geneva Pharmaceuticals, Inc.
Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 C and is useful for adjusting the plasma prolactin profile of a patient.Patent expiration dates:
- October 21, 2014✓
- October 21, 2014
Method for modifying and resetting the bloodstream prolactin levels of a human subject
Patent 5,716,957
Issued: February 10, 1998
Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
Assignee(s): The Board of Supervisors of Louisiana State and Agricultural and
Ergo Research Corporation
A process for the long term modification and regulation of lipid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species. The dopamine agonist is administered at the time of, or just after the time of peak plasma prolactin concentration found in lean animals of the same species and the prolactin stimulator is administered at a time just before the plasma prolactin rhythm reaches its peak in lean animals. Insulin resistance, and hyperinsulinemia or hyperglycemia, or both, can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity. The short term daily injections reset hormonal timing in the neural centers of the brain to produce long term effects.Patent expiration dates:
- February 10, 2015✓
- February 10, 2015
Therapeutic process for the treatment of the pathologies of type II diabetes
Patent 5,756,513
Issued: May 26, 1998
Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.Patent expiration dates:
- November 21, 2012✓
- November 21, 2012
Therapeutic process for the treatment of the pathologies of type II diabetes
Patent 5,866,584
Issued: February 2, 1999
Inventor(s): Cincotta; Anthony H. & Meier; Albert H.
Assignee(s): The Board of Supervisors of Louisiana State University and Agricultural
A process for the long term modification and regulation of lipid and carbohydrate metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these are the hallmarks of noninsulin dependent, or Type II diabetes)--by administration (i.e., by oral, sublingual or parenternal administration) to a vertebrate, animal or human, of a dopamine agonist, e.g., bromocriptine. Administration of the bromocriptine is made over a limited period at a time of day dependent on the normal circadian rhythm of insulin resistant and insulin sensitive members of a similar species. Insulin resistance, and hyperinsulinemia and hyperglycemia, or both, can be controlled in humans on a long term basis by such treatment inasmuch as the short term, daily administration resets hormonal timing in the neural centers of the brain to produce long term effects.Patent expiration dates:
- November 21, 2012✓
- November 21, 2012
Methods of identifying responders to dopamine agonist therapy
Patent 7,888,310
Issued: February 15, 2011
Inventor(s): Cincotta; Anthony H.
The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or fasting triglycerides are greater than about 150 mg/dl and/or said patient has blood pressure of greater than about 135/85 mm Hg. The present invention is also directed to treating identified patients with dopamine agonist therapy.Patent expiration dates:
- July 25, 2023✓
- July 25, 2023
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- May 5, 2012 - NEW PRODUCT
See also...
- Cycloset Consumer Information (Drugs.com)
- Cycloset Consumer Information (Wolters Kluwer)
- Cycloset Consumer Information (Cerner Multum)
- Cycloset Advanced Consumer Information (Micromedex)
- Bromocriptine Consumer Information (Wolters Kluwer)
- Bromocriptine Mesylate Consumer Information (Wolters Kluwer)
- Bromocriptine Consumer Information (Cerner Multum)
- Bromocriptine Advanced Consumer Information (Micromedex)
- Bromocriptine Mesylate AHFS DI Monographs (ASHP)
No comments:
Post a Comment